文献速递银屑病与炎症性皮肤病

抗血管内皮生长因子-A治疗:银屑病的新型个体化治疗方法

Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
PubMed 文献 · Br J Dermatol · 2022-03-17

慢性斑块状银屑病存在血管新生异常,血管内皮生长因子-A(VEGF-A)在皮损和血浆中上调。本文综述靶向VEGF-A在实验模型中的疗效及临床报告,提出部分高表达VEGF-A的患者可能从抗VEGF-A治疗中获益,为个体化治疗提供机会。

要点

  • VEGF-A在银屑病皮损和血浆中上调并介导血管新生。
  • 实验模型中靶向VEGF-A可使银屑病样炎症消退。
  • 部分高表达VEGF-A的银屑病患者可能最适合抗VEGF-A治疗。

核心结论

  • 抗VEGF-A治疗可能为银屑病提供替代抗细胞因子策略或与标准治疗互补的选择。
  • 存在高表达VEGF-A倾向的银屑病患者亚群可能最可能从抗VEGF-A治疗中获益。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 银屑病影响英国2%的人口,与皮外合并症和生活质量下降相关。
  • VEGF-A在银屑病患者皮损和血浆中上调,介导血管新生。
  • 实验模型中转基因表达VEGF-A可导致出现具有许多银屑病特征的皮肤病变。
  • 在银屑病样炎症的体内模型中靶向VEGF-A可使疾病消退。
  • 抗血管新生治疗广泛用于癌症和眼病,有临床报告接受VEGF-A抑制剂治疗的患者银屑病面积和严重度指数改善。

关键数值与推荐

  • 药物遗传学研究提示银屑病患者存在不同遗传特征,对应不同治疗反应性和疾病严重度。

临床怎么用

  • 抗VEGF-A治疗可能为银屑病管理提供替代现有抗细胞因子策略或与标准治疗互补的选择。
  • 部分高表达VEGF-A的银屑病患者亚群可能最可能从抗VEGF-A治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic plaque psoriasis is an inflammatory skin disease in which genetic predisposition along with environmental factors lead to the development of the disease, which affects 2% of the UK's population and is associated with extracutaneous morbidities and a reduced quality of life. A complex crosstalk between innate and adaptive immunity, the epithelia and the vasculature maintain the inflammatory milieu in psoriasis. Despite the development of promising treatment strategies, mostly targeting the immune system, treatments fail to fulfil every patient's goals. Vascular endothelial growth factor-A (VEGF-A) mediates angiogenesis and is upregulated in the plaques and plasma of patients with psoriasis. Transgenic expression of VEGF-A in experimental models led to the development of skin lesions that share many psoriasis features. Targeting VEGF-A in in vivo models of psoriasis-like inflammation resulted in disease clearance. Anti-angiogenesis treatments are widely used for cancer and eye disease and there are clinical reports of patients treated with VEGF-A inhibitors who have experienced Psoriasis Area and Severity Index improvement. Existing psoriasis treatments downregulate VEGF-A and angiogenesis as part of their therapeutic effect. Pharmacogenetics studies suggest the existence of different genetic signatures within patients with psoriasis that correspond with different treatment responsiveness and disease severity. There is a subset of patients with psoriasis with an increased predisposition to produce high levels of VEGF-A, who may be most likely to benefit from anti-VEGF-A therapy, offering an opportunity to personalize treatment in psoriasis. Anti-VEGF-A therapies may offer an alternative to existing anticytokine strategies or be complementary to standard treatments for the management of psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Luengas-Martinez A, Paus R, Young HS, et al. Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis. Br J Dermatol. 2022. PMID: 34878645. doi:10.1111/bjd.20940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。